VM1 Spółka z Ograniczoną Odpowiedzialnością (KRS 0000748189, NIP 7712902926) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. VM1 operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since September 7, 2018. VM1's most recently reported net revenue was 416.7 K PLN for 2024.
Historical suspension of activities
Suspension: September 19, 2023 - resumed: September 11, 2024
Negative equity
Negative equity in 3 of 6 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - VM1
Identity
- Name
- VM1 Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- September 7, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- June 5, 2025
- Founding act
- 05.09.2018 R.
Articles of association history (5)
- September 5, 2018: 05.09.2018 R.
- August 2, 2021: 02.08.2021, 6942/2021, NOTARIUSZ ZBIGNIEW EKIERT; KANCELARIA NOTARIALNA W GORZOWIE WIELKOPOLSKIM : ZMIANA PAR. 2, PAR. 3, PAR. 4 ORAZ PAR. 14 UMOWY SPÓŁKI
- March 3, 2022: 03.03.2022R. , REP A 1270/2021, NOTARIUSZ ANETA LESZCZYŃSKA; KANCELARIA NOTARIALNA W WARSZAWIE: ZMIANA §1, §2, §3 ORAZ §6 UMOWY SPÓŁKI
- September 16, 2024: 16.09.2024 R., REP. A NR 4958/2024, NOTARIUSZ RAFAŁ BRANDT, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA §4 ORAZ UCHYLENIE §15 UMOWY SPÓŁKI.
- October 21, 2024: 21.10.2024 R., REP. A NR 5461/2024, NOTARIUSZ RAFAŁ BRANDT, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA §5 ORAZ ZMIANA §14 UMOWY SPÓŁKI.
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
Other activities
Address and contact
- Address
- UL. POSTĘPU, 21B, 02-676, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- INFO@ORPHINIC.COM
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-59775-58472-DREEF-34
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - VM1
Credibility rating
46.2 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
34
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany nazwy spółki. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
3
3/8 yrs
Board changes
3
3/8 yrs
PKD changes
2
2/8 yrs
Name changes
2
2/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: D (46/100)
Trend: improving (+12.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2019–2024
Current: 11.1 K PLN
Safe: 3.3 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - VM1
Founded
September 7, 2018
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
7.5 K PLN
150 shares total
Shareholders
1
shareholder
Board
2 people
Proxies: 1
Filed years
6 years
2019–2024 · profitable: 1/6
Registry entries
24
latest: June 5, 2025
Risk signals
Revenue
416.7 K PLN
2024
Net profit
-87.4 K PLN
2024
Assets
1.4 M PLN
2024
Equity
1.4 M PLN
2024
Valuation
631.9 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - VM1.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
